Adaptive Testing Technologies (ATT) is a pioneering company in the field of mental health assessment systems using computerized adaptive testing. Founded in 2011, ATT is at the forefront of designing, testing, and implementing large-scale mental health assessment systems based on CAT. Their innovative approach has led to the development of precision mental and behavioral health testing and measurement software, enabling clients to offer evidence-based care to patients.
ATT's commitment to clinical validation sets them apart, offering the only clinically validated adaptive mental and behavioral health measures in the world. Operating primarily in the biotechnology and health care sectors, ATT is headquartered in the United States.
While specific details about their last investment and investors are not currently available, ATT's pioneering work in mental health assessment technology positions them as a compelling prospect for venture capital investment. With a strong track record and a unique offering in a growing industry, ATT presents an opportunity for investors looking to support innovative solutions in mental health care.